Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.95 | N/A | +3.04% |
management commentary, guidance changes, and full analysis available with Pro.
| +3.04% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value through our pipeline.
AbbVie's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 4.32% in reaction, likely due to the lack of revenue information and absence of forward guidance. Investors may be concerned about future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALPHABET INC Class C
Oct 24, 2023